Over the last 7 days, the United States market has risen 5.7%, contributing to a remarkable 37% increase over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable market conditions.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
AsiaFIN Holdings |
51.75% |
58.17% |
★★★★★★ |
|
Invivyd |
47.87% |
67.72% |
★★★★★★ |
|
Sarepta Therapeutics |
23.89% |
42.65% |
★★★★★★ |
|
TG Therapeutics |
34.66% |
56.48% |
★★★★★★ |
|
Alkami Technology |
21.89% |
98.60% |
★★★★★★ |
|
Alnylam Pharmaceuticals |
22.45% |
70.66% |
★★★★★★ |
|
Blueprint Medicines |
25.26% |
68.92% |
★★★★★★ |
|
Travere Therapeutics |
31.20% |
72.26% |
★★★★★★ |
|
Seagen |
22.57% |
71.80% |
★★★★★★ |
|
ImmunoGen |
26.00% |
45.85% |
★★★★★★ |
Click here to see the full list of 243 stocks from our US High Growth Tech and AI Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in therapies for rare neuroendocrine diseases, with a market capitalization of approximately $4.14 billion.
Operations: Rhythm Pharmaceuticals generates revenue primarily through the development and commercialization of therapies for patients with rare diseases, totaling $112.53 million. The company’s operations are centered on addressing rare neuroendocrine conditions.
Rhythm Pharmaceuticals stands out in the high-growth tech sector, primarily due to its innovative approach in tackling rare genetic disorders of obesity. With a projected annual revenue growth rate of 46.1%, Rhythm is pacing well above the US market average of 8.9%. This robust expansion is supported by significant R&D investments, which are crucial for advancing their pipeline and maintaining competitive edge in biotech innovation. The company’s recent earnings report revealed a revenue increase to $88.3 million from $53.19 million year-over-year, underscoring strong market demand for its specialized treatments like IMCIVREE® (setmelanotide). Moreover, earnings are expected to surge by 66.7% annually, highlighting potential profitability within three years—a testament to their strategic focus on addressing unmet medical needs through scientific research and development.
